CSL looks for long-term competitive edge as Vifor enters the fold - Sydney Morning Herald

Profits at the biotech giant declined in 2022 but boss Paul Perreault is looking beyond plasma collections to his newest purchase.

CSL will work swiftly to integrate Vifor, the kidney disease treatments maker it just bought, as chief executive Paul Perreault looks to position the company ahead of rivals for the long term. Share… [+1846 chars]

full article...